The specificity of JAK3 kinase inhibitors

被引：79

作者：

Changelian, Paul S. ^{[1
]}

Moshinsky, Deborah ^{[1
]}

Kuhn, Cyrille F. ^{[1
]}

Flanagan, Mark E. ^{[1
]}

Munchhof, Michael J. ^{[1
]}

Harris, Thomas M. ^{[1
]}

Doty, Jonathan L. ^{[1
]}

Sun, Jianmin ^{[1
]}

Kent, Craig R. ^{[1
]}

Magnuson, Kelly S. ^{[1
]}

Perregaux, David G. ^{[1
]}

Sawyer, Perry S. ^{[1
]}

Kudlacz, Elizabeth M. ^{[1
]}

机构：

[1] Pfizer Global Res & Dev, Groton, CT USA

来源：

BLOOD | 2008年 / 111卷 / 04期

关键词：

D O I：

10.1182/blood-2007-09-115030

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

PF-956980 is a selective inhibitor of JAK3, related in structure to CP-690550, a compound being evaluated in clinical trials for rheumatoid arthritis and prevention of allograft rejection. PF-956980 has been evaluated against a panel of 30 kinases, and found to have nanomolar potency against only JAK3. Cellular and whole blood activity of this compound parallels its potency and selectivity in enzyme assays. It was effective in vivo at inhibiting the delayed type hypersensivity reaction in mice. We compared 2 commercially available JAK3 inhibitors (WHI-P131 and WHI-P154) in the same panel of biochemical and cellular assays and found them to be neither potent nor selective for JAK3. Both were found to be nanomolar inhibitors of the EGF receptor family of kinases. As these compounds have been used in numerous publications in the transplant and autoimmune disease literature, their specificity should be considered when interpreting these results.

引用

页码：2155 / 2157

页数：3

共 11 条

[1] An epigenetic view of helper T cell differentiation [J].

Ansel, KM ;

Lee, DU ;

Rao, A .

NATURE IMMUNOLOGY, 2003, 4 (07) :616-623

[2] JAK kinase inhibitors [J].

Burns, C ;

Wilks, A ;

Su, S .

DRUG DISCOVERY TODAY, 2004, 9 (16) :694-695

[3]

Busque S, 2007, AM J TRANSPLANT, V7, P304

[4] Targeting JAK3 with JANEX-1 for prevention of autoimmune type 1 diabetes in NOD mice [J].

Cetkovic-Cvrlje, M ;

Dragt, AL ;

Vassilev, A ;

Liu, XP ;

Uckun, FM .

CLINICAL IMMUNOLOGY, 2003, 106 (03) :213-225

[5] Therapeutic potential of Janus kinase 3 (JAK3) inhibitors [J].

Cetkovic-Cyrlje, M ;

Tibbles, HE .

CURRENT PHARMACEUTICAL DESIGN, 2004, 10 (15) :1767-1784

[6] Prevention of organ allograft rejection by a specific Janus kinase 3 inhibitor [J].

Changelian, PS ;

Flanagan, ME ;

Ball, DJ ;

Kent, CR ;

Magnuson, KS ;

Martin, WH ;

Rizzuti, BJ ;

Sawyer, PS ;

Perry, BD ;

Brissette, WH ;

McCurdy, SP ;

Kudlacz, EM ;

Conklyn, MJ ;

Elliott, EA ;

Koslov, ER ;

Fisher, MB ;

Strelevitz, TJ ;

Yoon, K ;

Whipple, DA ;

Sun, JM ;

Munchhof, MJ ;

Doty, JL ;

Casavant, JM ;

Blumenkopf, TA ;

Hines, M ;

Brown, MF ;

Lillie, BM ;

Subramanyam, C ;

Shang-Poa, C ;

Milici, AJ ;

Beckius, GE ;

Moyer, JD ;

Su, CY ;

Woodworth, TG ;

Gaweco, AS ;

Beals, CR ;

Littman, BH ;

Fisher, DA ;

Smith, JF ;

Zagouras, P ;

Magna, HA ;

Saltarelli, MJ ;

Johnson, KS ;

Nelms, LF ;

Des Etages, SG ;

Hayes, LS ;

Kawabata, TT ;

Finco-Kent, D ;

Baker, DL ;

Larson, M .

SCIENCE, 2003, 302 (5646) :875-878

[7]

KREMER JM, 2006, AM COLL RHEUM ANN M

[8]

Kudlacz E, 2004, AM J TRANSPLANT, V4, P51, DOI 10.1046/j.1600-6143.2003.00281.x

[9]

Lu BF, 1997, J IMMUNOL, V159, P1255

[10] PHARMACOLOGICAL MANIPULATION OF A 4 DAY MURINE DELAYED-TYPE HYPERSENSITIVITY MODEL [J].

ROUDEBUSH, RE ;

BRYANT, HU .

AGENTS AND ACTIONS, 1993, 38 (1-2) :116-121

← 1 2 →